Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT162b2 bivalent + VaxigripTetra
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This entry refers to a co-administration regimen consisting of the bivalent mRNA COVID-19 vaccine (BNT162b2) and the quadrivalent inactivated influenza vaccine (VaxigripTetra). The bivalent mRNA vaccine, developed by Pfizer and BioNTech, targets the spike protein of the original SARS-CoV-2 strain and the Omicron BA.4/BA.5 variants. VaxigripTetra, developed by Sanofi, is a split-virion inactivated vaccine containing antigens from four influenza strains: two influenza A (H1N1 and H3N2) and two influenza B (Victoria and Yamagata lineages). This combination is being evaluated in clinical trials, such as those conducted by the Prince of Songkla University, to assess the safety and immunogenicity of simultaneous booster administration for both COVID-19 and seasonal influenza in healthy adults.
- Brand names
- ComirnatyVaxigripTetra
- Other names
- Bivalent mRNA SARS-CoV-2 vaccine-Prince of Songkla University-COVID-19-influenzaBivalent mRNA BNT162b2 + Quadrivalent Influenza Vaccine
02
Targets
SARS-CoV-2 spikeHA (Hemagglutinin)
Beyond the preview
Go deeper on BNT162b2 bivalent + VaxigripTetra.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT162b2 bivalent + VaxigripTetra.